Application of isoglycyrrhizin to preparation of antianxiety drugs

An isoliquiritigenin and anti-anxiety technology, which is applied in the field of medicine, can solve the problem of anti-anxiety that has not been seen with isoliquiritigenin, and achieve the effects of inhibiting occurrence and/or development, avoiding damage, and improving anxiety

CN110384690APending Publication Date: 2019-10-29SHANGHAI UNIV OF T C M
3 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2019-10-29

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of medicines, and particularly relates to new use of isoglycyrrhizin in anti-anxiety, especially the anti-anxiety of alzheimer disease in the early stage. The isoglycyrrhizin can relieve anxiety symptoms of alzheimer disease in a highly active state in the early stage by improving anxiety behaviors such as the emotional lability and the somatic movement lability,the damage of the anxiety symptoms on the cognitive function and the executive capacity is avoided, development and / or progression of alzheimer disease are / is improved and / or inhibited, obvious toxic and side effects are avoided, and a new therapeutic drug for prevention and / or treatment of anxiety disorder, especially the early anxiety of alzheimer disease.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of medicine, and in particular relates to the new application of isoliquiritigenin in anti-anxiety, especially early anti-anxiety of Alzheimer's disease. Background technique

[0002] Anxiety is a reflection of people's fear or stress. It is a very common mental illness. Every year, 1% of the world's population is disabled due to anxiety, and 16.8% of the population in the UK suffers from anxiety disorders. It also affects about 400,000 American adults. Anxiety disorders are mainly manifested as symptoms such as body tremors, palpitations, muscle tension, mental tension, irritability, insomnia, and persistent worry.

[0003] In the early stage (adolescence) of Alzheimer's disease patients, neuropsychiatric symptoms such as apathy, anxiety, irritability, appetite and sleep disturbance will appear before the obvious symptoms of memory impairment. This pathological manifestation is also called dementia mental behavior ...

Examples

Embodiment Construction

[0020] The present invention will be further illustrated in detail below in conjunction with specific embodiments. It should be noted that the descriptions of these embodiments are used to help understanding of the present invention, but are not intended to limit the present invention.

[0021] (1) Experimental animals: AD animal models are conditional PS1 / PS2 double knockout (PS1 / PS2 conditional double knockout, PS cDKO) mice, referred to as PS cDKO mice, with genotypes of Cre+ / -, PS1f / f, PS2- / - are PS cDKO mice; genotypes Cre+ / -, PS1+ / +, PS2+ / + are wild-type control mice, and the animals have free access to food and water, kept at room temperature 21±2°C, humidity (45 %~65%) and alternating light and dark (12h︰12h) environment. All experimental animal operations complied with the regulations of experimental animal ethics and biomedical ethics review methods.

[0022] (2) Drugs: Isoliquiritigenin (ISL) was purchased from Shanghai Tongtian Biology, product number: 1601262, M...